منابع مشابه
Empagliflozin and the Prevention of Heart€Failure
SEE PAGE 347 H eart failure develops in more than 1 in 5 patients with diabetes mellitus (DM) older than 65 years of age and augers an extremely poor prognosis, with a median survival of approximately 4 years. The landmark EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) showed that empagliflozin significantly reduced the primary composite...
متن کاملIs there any difference between Vitamin D deficiency among heart failure and Non-heart failure elderly with cardiovascular disease?
Vitamin D deficiency is common among the elderly with and without heart failure (HF). This study was designed to identify the degree of vitamin D deficiency among HF and Non- HF elderly with cardiovascular disease. In this study, fifty hospitalized elderly patients with HF (26 women and 24 men, age range 60-90 years) and fifty elderly without HF were randomly selected. The level of serum 25-hyd...
متن کاملWomen, heart failure, and heart failure therapies.
The landmark 2001 Institute of Medicine (IOM) report Exploring the Biological Contributions to Human Health: Does Sex Matter?1 confirmed that significant differences between the sexes affect the prevalence, incidence, and severity of a broad range of diseases and conditions. The report highlighted that sex differences must be considered when designing and analyzing research studies in all areas...
متن کاملHodgkin’s Lymphoma Presenting with Myocardial Metastasis and Heart Failure
Although involvement of the heart by malignant lymphoma is relatively common, it is unusual to be detected premortem. We report a case of Hodgkin's lymphoma who presented with systemic signs and symptoms including abdominal distension, weakness, pallor, chills and fever, hepatosplenomegaly and generalize...
متن کاملEmerging Drug Therapies for Heart Failure
Heart failure is associated with high morbidity and mortality and is proving to be an economic burden in developing countries. A number of therapeutic agents are presently employed in heart failure; but they are not sufficient to control symptoms of heart failure. Moreover, the prevalence of chronic heart failure is progressively increasing and thus there is a continuing need to develop effecti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2019
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.119.040921